Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
Portfolio Pulse from Vandana Singh
Amgen Inc. (NASDAQ: AMGN) reported mixed Q2 results, with analysts focusing on the potential of its obesity drug, MariTide. Despite underperformance in its base business, analysts remain optimistic about Amgen's long-term growth prospects, maintaining positive ratings and high price targets.
August 07, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen reported mixed Q2 results, with underperformance in its base business but potential in its obesity drug, MariTide. Analysts maintain positive ratings and high price targets, focusing on long-term growth prospects.
Despite mixed Q2 results, analysts are optimistic about Amgen's long-term growth, particularly due to the potential of its obesity drug, MariTide. Positive ratings and high price targets suggest a likely positive short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100